Ъѹ
TH EN
Ъѹ

 


ǽҡ >> Ԩ
ʶҺѹآҾҡ¼š֡ ADVANCE-ON ǡѺѹԵдѺӵʹ

ѹ 24 .. 2557 )
 
 ¹, --22 ..--/Թʷ

          äǺдѺӵʹҧ觤ѴŴ㹼äҹ 2 »

          ѡҧҨ觼Ŵյ

          йѡԨ¨ҡ¤鹾 äǺдѺӵʹͧäҹ 2 ҧ觤Ѵ öŴ»ѧ¡ѺѺѡẺ

          š֡дѺš駹 Ҽҹ 5 դѧش gliclazide MR ŴдѺӵʹҧ觤Ѵ Ҽäҹ 2 ѧҡԴ¨ͧӡÿ͡ͻ١ ǡѹդ§ŴŧªԵԴäʹʹ

          ʶҺѹآҾҡ (George Institute for Global Health: GIGH) ᡹㹡Ԩ ADVANCE-ON 20 ͵ԴšѡҼ 8,500 ҡҡ 11,000 ÷ͧ ADVANCE ͻ 2544 ¼š֡Ҿ ·ѺäǺдѺӵʹҧ觤Ѵ gliclazide MR դ§㹡Դ¹ŧ ѧҡѺѺѡҵ㹻 2551

          ͧʵҨ ٹ ҡʶҺѹآҾҡԷ«Դ 繼ӹ¡áԨ ҧûЪҤ֡äҹû (European Association for the Study of Diabetes: EASD) ¹ "šԨӶ֧ӤѭͧäǺдѺӵʹҧͧջԷҾ 觪»ͧѹ㹼äҹ 2
 
          "ŴдѺӵʹҧ觤ѴԸմѧ繻ªҧҡͧûͧѹ ѧԴѹա”

          "ѡҧҨ觼Ŵյǔ

          ҹʵҨ ˹ҡԨ "÷ͧ ADVANCE-ON Ѻ դӤѭͼäҹ
 
          2 ѻ͹ ʵҨʹ͢ǡѺѹԵҡ÷ͧ ADVANCE-ON ͷЪҤäû (European Cardiology Society Congress) Ź ѧҡʹա駵ͷЪ EASD ¹

          "ŴѹԵѵҡªԵҡä˵Ŵŧ ¼Ѿѧҹ» Ŵŧ ѧ鹤աäǺѹԵ perindopril indapamide ҧͧǔ
 
          աûԹҷšռäҹ 382 ҹ лҳ 90% ͧӹǹѧǻäҹ 2 äҹ˵ѡԴä

          äҹ˵آͧä Һʹ õͧѴз äʹʹͧ ͡ҡѧԴ 1 10 ˵ѡͧªԵ 㹺ôҡçǶ֧ҧ鹹 äشäդ˹㹡ѡҹ·ش㹪ǧ 20 շҹ

          ÷ͧ ADVANCE ѺعʹѺʹعҡԨ·ҧᾷآҾ觪ҵԢͧ (NHMRC) ŹԸä㨢ͧѧ ҤäҹҪҳҨѡ

          ǡѺʶҺѹآҾҡ

          ʶҺѹآҾҡ 蹾ѲҤسҾԵͧ餹ҹšҹԨ´ҹآҾѹѹ ҧʶҺѹԹҹҹآҾҧͺ աԨ·ҧԹԡ Ъҡ кآҾ ըش¹ŧǻԺѵйº´ҹآҾš ҧʶҺѹ͢¼ǪҭҧᾷآҾš 觷ӧҹѹѺ͡Ѻ˵ѡͧªԵзؾҾҧ 駹 ʶҺѹ͵駢ѺԷ«Դ ѨغѹҧʶҺѹӹѡҹ㹨չ Թ ҪҳҨѡ ѧҹѺٹԷʵآҾͧԷ»ѡ ԷҺѴ Է͡촴

          ʶҺѹӤѭѺԨ·ҧԹԡآҾЪҡ Ѿö任ءԧҧ´ 駡Դ¹ŧҹºǻԺѵҧԧѹ ʶҺѹ쨵Դ 1 10 ʶҺѹçԷԾŢͧš㹪ǧ»շҹ ҹԨ¢ͧʶҺѹ¹ŧǷҧҹᾷԸդԴǡѺѡäҧš ҷ þѲǷҧѡѺäʹʹͧ ʴҡŴѹԵŴ§ͧäʹʹ㹼äҹ ֧ùʹùӷʹҡѺ·ͧ繾 駹 þѲԸշա㹡ôآҾ繾ѹԨѡͧʶҺѹ

          ŪԴ
         
          ֡ҴҹŪ   
          ʶҺѹآҾҡ
          . +61-410-411-983
          : emartel@georgeinstitute.org.au

          觢: ʶҺѹآҾҡ         



ǡѺ

  • ѵ
  • ҷ˹ҷ
  • ·ȹ
  • Һó
  • ˹§ҹ
  • ˹§ҹ

  • ʶҹ÷ȹ

  • 䫵ʶҹԷ÷ȹ
  • ÷ȹЪѹ

    ʶҹԷ

  • 䫵ʶҹԷءШ§

  • ѧԷءЪѹ

  • ԡâͧЪѹ

    line Ъѹ
     


    © ʧǹԢԷ Ъѹ Ţ 9 .ѹ . 6 ǧ ࢵ ا෾ 10400
    Ѿҧ : 02-6182323 Ҵ:51274 : 02-6182364,02-6182399 E-mail webmaster@prd.go.th
    Facebook Twitter Barcode